BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HUTCHMED readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies HUTCHMED's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05374603-2032@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT05374603)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Adva
 nced or Metastatic NSCLC\nEstimated primary completion: 18 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05374603
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009836-2032@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Orpathys (Savolitinib): Phase 3 readout est. (NCT05009836)
DESCRIPTION:Orpathys (Savolitinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+
 /MET+ Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 
 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/savoliti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05009836
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06584032-2237@assetmemo.bio
DTSTAMP:20261121T004959Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Fruzaqla / Elunate (Fruquintinib): Phase 3 readout est. (NCT0658403
 2)
DESCRIPTION:Fruzaqla / Elunate (Fruquintinib)\, phase 3\, Endometrial Cance
 r.\nStudy: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced
  Endometrial Cancer\nEstimated primary completion: 8 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/fruquintinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06584032
URL:https://assetmemo.bio/drug/fruquintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
